Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors, of which the relative importance is unknown. Objective Our aim was to …

Background Treatment failure during venom immunotherapy (VIT) may be associated with a
variety of risk factors. Objective Our aim was to evaluate the association of baseline serum …

BACKGROUND: Severe side effects during venom immunotherapy (VIT) are associated with
a variety of risk factors. OBJECTIVE: Our aim was to evaluate the association of baseline …

Background: Up to 20% of patients allergic to Hymenoptera venom are not protected by
conventional venom immunotherapy (VIT) with 100 μg of any single venom. Objective: We …

Background Up to 75% of patients with severe anaphylactic reactions after Hymenoptera
sting are at risk of further severe reactions if re-stung. Venom immunotherapy (VIT) is highly …

Background Adverse systemic reactions (SR s) are more common in honeybee venom
immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SR s during the …

Background: Venom immunotherapy is a generally accepted treatment for serious allergy to
bee and yellow jacket venom. However, it is not precisely known to whom venom …

Background There is an ongoing debate on whether angiotensin‐converting enzyme
inhibitors (ACEI) should be substituted prior to initiation of venom immunotherapy (VIT) for …

Advances in hymenoptera venom immunotherapy : Current Opinion in Allergy and Clinical
Immunology Advances in hymenoptera venom immunotherapy : Current Opinion in Allergy and …

Background: Hymenoptera venom immunotherapy in allergic patients is a well-established
treatment modality for the prevention of systemic anaphylactic reactions caused by insect …